CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB) Meeting Abstract
| Authors: | Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H. |
| Abstract Title: | CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB) |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 41 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2018 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2018-09-01 |
| Start Page: | 268 |
| End Page: | 269 |
| Language: | English |
| ACCESSION: | WOS:000446816500654 |
| PROVIDER: | wos |
| PUBMED: | 30261496 |
| DOI: | 10.1159/000492737 |
| Notes: | Meeting Abstract: V844 -- Source: Wos |
